Follow-The-Filings

Security · featured owners

ARWR Arrowhead Pharmaceuticals In

Health Care COM Equity as of 2026 Q2 among managers we track

  • 1 Owner
  • $539K
  • 1 new 1 exit

ARWR (Arrowhead Pharmaceuticals In) is held in 1 featured 13F book as of 2026 Q2. Polen Capital Management is the largest tracked holder by portfolio weight. Figures are as-filed 13F, not free float.

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Polen Capital Management 2026 Q2 <0.01% New <0.01% 6,612 $539K history
Farallon Capital Management exited 2026 Q2 last 2026 Q1 0.01% Exit −0.01% 15,800 $991K history

1 current · 1 exited last period · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $240.74M $3.55M $829.45M
Net income -$205.28M -$599.49M -$1.63M
Net margin * -85.3% -16882.4% -0.2%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $419.52M $695.47M $950.64M
Total non-current assets * $346.03M $444.33M $434.66M
Total assets $0.766B $1.14B $1.39B
Total current liabilities $105.46M $103.17M $195.49M
Total non-current liabilities $372.93M $845.57M $686.39M
Total equity $271.34M $185.44M $466.05M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$153.89M -$462.85M $179.55M
Cash from investing -$96.16M -$420.07M -$129.29M
Cash from financing $253.05M $870.52M $74.01M
Net change in cash * $3.01M -$12.4M $124.26M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders